

Communication

Use of the Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 variant RBDs

Enqing Tan ¹, Erica Frew ¹, Jeff Cooper ², John Humphrey ², Matthew Holden ¹, Amanda Restell Mand ¹, Jun Li ², Shaya Anderson ², Ming Bi ², Julia Hatler ², Anthony Person ², Frank Mortari ³, Kevin Gould ^{4,*}, and Shelly Barry ^{1,*}

Bio-Techne Corporation, 614 McKinley Place NE, Minneapolis, MN 55413, USA;

¹ Diagnostic Reagents Division, Devens site, MA 01434, USA; Enqing.Tan@bio-technne.com (E.T.); Erica.Frew@bio-technne.com (E.F.); Matthew.Holden@bio-technne.com (M.H.); Amanda.Mand@bio-technne.com (A.M.);

² Reagent Solutions Division, Minneapolis site, MN 55413, USA; Jeff.Cooper@bio-technne.com (J.C.); John.Humphrey@bio-technne.com (J.H.); Jun.Li@bio-technne.com (J.L.); Shaya.Anderson@bio-technne.com (S.A.); Ming.Bi@bio-technne.com (M.B.); Julia.Hatler@bio-technne.com (J.H.); Anthony.Person@bio-technne.com (A.P.);

³ Corporate Development, Minneapolis site, MN 55413, USA; Frank.Mortari@bio-technne.com (F.M.);

⁴ Diagnostic Reagents Division, San Marcos site, CA 92078, USA;

* Correspondence: Shelly.Barry@bio-technne.com (S.B.); Kevin.Gould@bio-technne.com (K.G.);

Abstract: Identifying anti-spike antibodies that exhibit strong neutralizing activity against current dominant circulating variants and antibodies that are escaped by these variants have important implications in the development of therapeutic and diagnostic solutions as well as in improving understanding of the humoral response to SARS-CoV-2 infection. We characterized seven anti-RBD monoclonal antibodies for their binding activity, pairing capability and neutralization activity to SARS-CoV-2 and three variant RBDs (UK, SA and BR P.1) via lateral flow immunoassays. The results allowed us to group these antibodies into three distinct epitope bins. Our studies showed that two antibodies had broadly potent neutralizing activity against SARS-CoV-2 and these variant RBDs and that one antibody did not neutralize the SA and BR P.1 RBDs. The antibody escaped by the SA and BR P.1 RBDs retained binding activity to SA and BR P.1 RBDs but was unable to induce neutralization. Further, we demonstrated that the lateral flow immunoassay can be a rapid and effective tool for antibody characterization, including epitope classification and antibody neutralization kinetics. From these studies, the potential contributions of the mutations (N501Y, E484K and K417N/T) contained in these variants' RBDs on antibody pairing capability, neutralization activity and therapeutic antibody targeting strategy are discussed.

Keywords: COVID-19; SARS-CoV-2 variant; lateral flow immunoassay; spike protein; receptor binding domain (RBD); neutralizing antibody; therapeutic antibody cocktail; epitope binning; rapid neutralization test; ACE2;

1. Introduction

The continued emergence of SARS-CoV-2 variants has raised concerns and challenges for the control, prevention and management of the coronavirus disease (COVID-19) [1]. Currently, the circulating variants of greatest concern include the United Kingdom variant (B.1.1.7 lineage, UK) [2,3], the South African variant (B.1.351 lineage, SA) [4], the Brazilian variant P.1 (B.1.1.28.1 lineage, BR P.1) [5], the Brazilian variant P.2 (B.1.1.28.2 lineage, BR P.2) [6], the Denmark mink variant (B.1.1.298 lineage, DM) [7], the California variants (B.1.429/427 lineage, CA) [8], the New York variants (B.1.526/525 lineage, NY) [9], and the more recent Indian variant (B.1.617 lineage, IN) [10]. In the absence of an effective strategy to curb the spread of SARS-CoV-2 virus infection and more individuals harboring the virus, it is inevitable that more variants are likely to emerge.

The SARS-CoV-2 virus infects mammalian cells by attaching transmembrane spike proteins (S protein) to angiotensin-converting enzyme 2 receptors (ACE2) found on the surface of human target cells [11, 12]. Hence, inhibiting the binding of SARS-CoV-2 spike protein to ACE2 has been the primary strategy behind most SARS-CoV-2 vaccines [13, 14], therapeutic antibodies [15, 16], and therapeutic soluble ACE2 molecules [17]. It is evident that the receptor binding domain (RBD) of the viral spike protein plays a critical role in the binding of SARS-CoV-2 to ACE2.

As of May 14, 2021, there are two therapeutic neutralizing antibody cocktails in use for the treatment of COVID-19 patients that have received Emergency Use Authorization from the FDA [15, 16]. Regeneron’s REGN-COV2 is a combination of two anti-SARS-CoV-2 RBD monoclonal antibodies (REGN10933 and REGN10987), and Eli Lilly’s cocktail is a combination of two anti-SARS-CoV-2 RBD monoclonal antibodies (LY-CoV555 and LY-CoV016). The emergence of SARS-CoV-2 variants have unfortunately caused monoclonal antibody therapies and spike protein-based vaccines to be less effective than determined in the original clinical studies [18,19]. In fact, due to the sustained increase in COVID-19 viral variants that are resistant to LY-CoV555 antibody, the FDA recently revoked the Emergency Use Authorization for this monoclonal antibody (LY-CoV555) monotherapy [20].

SARS-CoV-2 variants contain numerous mutations and/or deletions along the entire viral spike protein, but this report focuses on the key mutations in the RBD that have a direct impact on RBD-ACE2 interaction and the escape mechanism of virus from neutralizing antibodies. **Figure 1** summarizes currently circulating SARS-CoV-2 variants and their respective mutations within the spike RBD, which include: N501Y in the UK, SA, and BR-P.1 variants [2,3]; E484K/Q in the SA, BR P.1, BR P.2, NY and IN variants [3,10]; K417N/T in the SA and BR P.1 variants [5,6]; L452R in the CA and IN variants [8,10]; and Y453F in the Denmark mink variant [7]. These mutations cause a higher rate of viral infectivity, enhanced disease severity, and escape the antibody neutralization action, resulting in reduced vaccine efficacy [2,4,7,18]. By completely mapping the SARS-CoV-2 RBD mutations, Starr et. al. was able to demonstrate that the RBD containing the E484K mutation escapes LY-CoV555 antibody, while the RBD containing the K417N/T mutations escapes LY-CoV016 antibody [21].




Figure 1. Mutations in the spike RBD protein of currently circulating SARS-CoV-2 variants [2-10]. (Top panel) Variants included in this study. (Bottom panel) Variants not addressed in this study.

To better understand how mutations mediate escape from antibody neutralizing activity and to identify anti-RBD antibodies for potential diagnostic and therapeutic uses against SARS-CoV-2 variant infection, we employed a straightforward lateral flow immunoassay to characterize seven anti-RBD monoclonal antibodies for their binding activity, immunoassay pairing capability and neutralizing activity to SARS-CoV-2 RBD and the UK, SA and BR P.1 variant RBDs. The objectives were three-fold: (1) to screen and identify variant-specific antibodies or escaped neutralizing antibodies for potential diagnostic applications, (2) to characterize and identify broadly potent neutralizing antibodies against SARS-CoV-2 and the variant RBDs for improved neutralization strategies, and (3) to explore the use of rapid lateral flow-based dipstick assay and cassette assay (LFA) for such studies. Using this simple LFA assay, we report our findings that two of the seven antibodies studied showed broad, potent neutralizing activity against all four RBDs; one antibody had strong neutralizing activity against the SARS-CoV-2 and UK variant RBDs, but was unable to neutralize the SA and BR P.1 variant RBDs; and a combination of two antibodies from different epitope bins produced an additive effect in the neutralization activity against all four RBDs.

2. Materials and Methods

2.1. Materials

2.1.1. Anti-SARS-CoV-2 RBD antibodies

Seven anti-SARS-CoV-2 spike RBD murine monoclonal antibodies (Ab1-Ab7) were selected for this study. Ab1 (clone No. 1035709), Ab2 (clone No. 1035740), Ab3 (clone No. 1035753) and Ab4 (clone No. 1035762) were generated using SF21-derived SARS-CoV-2 S1 subunit as the immunogen. Ab5 (clone No. 1035419) was generated using HEK293-derived SARS-CoV-2 RBD (R319-F541) protein as the immunogen. Ab6 (clone No. 1035224) and Ab7 (clone No. 1035240) were generated using SARS-CoV-2 S1 subunit as the immunogen in a separate fusion. Two anti-nucleocapsid protein monoclonal antibodies (clone No. 1035101 and clone No. 1035138), generated using SARS-CoV-2 nucleocapsid full-length protein as the immunogen, were used as negative controls. All antibodies used were produced by Bio-Techne Corporation (Minneapolis, MN).

2.1.2. Recombinant SARS-CoV-2 and variant RBDs

All recombinant RBD proteins were generated by Bio-Techne Corporation (Minneapolis, MN) corresponding to NCBI reference sequence accession number YP_009724390.1 [22], using the HEK293 expression system. These proteins include the SARS-CoV-2 RBD (R319-F541), the UK variant RBD (R319-F541 with N501Y), the SA variant RBD (R319-F541 with K417N, E484K, N501Y), and the BR P.1 variant RBD (R319-F541 with K417T, E484K, N501Y). Secreted recombinant proteins were purified from the conditioned media by nickel chelating chromatography, followed by size exclusion chromatography. All recombinant RBD constructs include a C-terminal 6-His tag.

2.1.3. Other materials

Triton X-100, 30% bovine serum albumin (BSA) solution, 30% Brij-35 solution, 10x phosphate buffered saline (PBS), and other chemicals were purchased from Millipore-Sigma (Burlington, MA). Casein solution (1%, w/v) in Tris buffer, pH 7.4, was purchased from Thermo Fisher Scientific (Waltham, MA). Recombinant human ACE2 protein, goat polyclonal anti-chicken IgY antibody and chicken IgY protein (cIgY) were from Bio-Techne Corporation (Minneapolis, MN).

2.2. Lateral flow dipstick, neutralization test devices and lateral flow immunoassay

2.2.1. Preparation of antibody-AuNP conjugate

Anti-RBD and anti-nucleocapsid antibodies were coated onto 40 nm citrate protected gold nanoparticles (AuNP, nanoComposix, San Diego, CA) using a direct adsorption using a modified procedure from the manufacturer. Briefly, AuNP solution of 20 OD was combined with high purity water at 1:4 volume/volume ratio (1 part of 20 OD AuNP solution in 0.02 mM sodium citrate and 4 parts of water). Antibody suspended in 1x PBS was added to the AuNP solution at 5% or less of the total reaction volume, with the antibody to AuNP ratio of 50 µg antibody per mL of 20 OD AuNP. Due to partial particle aggregation during the adsorption process, the amount of Ab7 was reduced to 20 µg per mL 20 OD AuNP solution. For the discriminative binding study, Ab4 and Ab5 were coated at 20 µg per mL of 20 OD AuNP solution. After the AuNP and antibody mixture was incubated at ambient room temperature for 30 minutes, BSA was added to a final concentration of 5 mg/mL to block the remaining AuNP surface reactivity. After another 30-minute incubation period, the AuNP and antibody conjugate solution was centrifuged at 3800 RCF for 10 minutes to pellet the antibody-AuNP (Ab-AuNP) conjugate. The conjugate was washed twice with wash and storage buffer, then finally re-suspended in wash and storage buffer and stored at 4°C until use. The optical density of the conjugate solution was confirmed by an absorbance reading at 525 nm using a NanoDrop 2000 spectrophotometer. The wash and storage buffer is composed of 0.05x PBS, pH 7.4, containing 0.5% (w/v) BSA and 0.05% (w/v) sodium azide.

2.2.2. Lateral flow dipstick and assay procedure for antibody pairing capability and epitope binning

Each dipstick consists of a polystyrene card backing with a 25 mm nitrocellulose membrane and a 17 mm absorbent pad. Dipsticks were prepared using a 60 mm x 300 mm FF120HP Whatman membrane card (Cytiva, Marlborough, MA). The 20 mm wide adhesive portion was removed using a paper cutter, then a 17 mm x 300 mm cellulose fiber sample pad strip (Millipore-Sigma, Burlington MA) was attached to the 15 mm wide adhesive portion as the absorbent pad with ~2 mm overlapping the nitrocellulose membrane. The card assembly was cut into 40 mm wide sections (dipsticks) using a Matrix 2360 Programmable Shear.

Dipsticks were then spotted with a nine-spot protein array: 7 spots for the anti-RBD antibodies and two spots for negative controls (i.e. the anti-NP antibody and BSA). Each protein was diluted to 1 mg/mL in 1x PBS, pH 7.4 and manually pipetted onto the nitrocellulose membrane at 1 µL per spot. The coated dipsticks were dried in a 37°C oven with circulating air for a minimum of 30 minutes prior to use; longer term storage was in a plastic bag with desiccant.

Immediately prior to running an assay for the epitope binning and pairing capability study, a 300 µL sample mixture was prepared by mixing three solutions: 150 µL RBD (1 µg/mL) in assay run buffer, 80 µL ab-AuNP conjugate (4 OD) in wash and storage buffer, and 70 µL assay run buffer. To start the assay, a spotted dipstick was placed in a reservoir with the nitrocellulose end at the bottom and then the freshly prepared sample mixture was transferred into the reservoir, allowing the sample mixture to flow up the nitrocellulose membrane to the absorbent pad. After the sample mixture ran for 12-15 minutes, an additional 250 µL assay run buffer was added to rinse off any unbound material for another 12-15 minutes. Thus, each assay run took approximately 30 minutes. For the antibodies with good pairing capability, RBD protein would bind to Ab-AuNP detector and then be captured by the spotted antibody to form a red-colored crescent line or circular spot (i.e. sandwich assay). For the antibodies with poor pairing capability, RBD-Ab-AuNP complex would not be captured by the spotted antibody, producing little to no color change. The assay run buffer consists of 1x PBS, pH 7.4, with 1.5% (w/v) BSA, 0.25% (w/v) Tween-20, 0.2% (w/v) casein, and 0.025% (w/v) sodium azide.

The assay procedure for evaluating the comparative binding characteristics to four RBD proteins was further modified for better assay sensitivity and specificity. All steps were the same as the above procedure for the epitope binning and pairing capability study, except the 300 μ L sample mixture was prepared by mixing three solutions: 50 μ L RBD in Brij-35 assay buffer, 40 μ L Ab-AuNP conjugate (4 OD) in wash and storage buffer, and 210 μ L Brij-35 assay buffer. Brij-35 assay buffer (210 μ L per dipstick) was also used as the assay run buffer. The Brij-35 assay buffer was composed of 1x PBS, pH 7.4, containing 1% (w/v) BSA, 0.1% (v/v) TX-100, 0.3% (v/v) Brij-35, 0.3% (w/v) casein and 0.05% (w/v) sodium azide.

At the end of an assay, each dipstick was imaged using an iPhone camera to document the assay results.

2.2.3. Lateral flow cassette and assay procedure for neutralization kinetics

Lateral flow neutralization test devices were developed and manufactured according to the procedures developed in our laboratory. Briefly, recombinant human ACE2 was striped in the "test zone" and goat polyclonal anti-chicken IgY antibody was striped in the "control zone" as the capture agent, using an IsoFlow Reagent Dispenser. Recombinant RBD and cIgY were conjugated to the 40 nm gold nanoparticles as the detectors for the test zone and the control zone, respectively. The AuNP-RBD and AuNP-cIgY conjugates were combined in a drying down buffer containing salt, stabilizer and AuNP releasing agents and sprayed onto conjugate pad strips using an IsoFlow Reagent Dispenser. Sprayed conjugate pad strips were dried in a 37°C oven and then stored in a sealed foil pouch with desiccants until use. By alternating the AuNP-RBD conjugate while keeping other components the same, four types of rapid neutralizing antibody test cassettes were prepared for the SARS-CoV-2 RBD, the UK variant RBD, the SA variant RBD and the BR P.1 variant RBD.

The neutralization antibody test strip consists of a plastic backing card attached with a sample pad, a conjugate pad with dried gold conjugate detectors, a nitrocellulose membrane striped with the capture antibodies, and an absorbent (wicking) pad. Each test strip was assembled into a plastic cassette and sealed in a foil pouch with desiccant, stored at ambient room temperature. The dropper bottle used for introducing the neutralization assay buffer has a drop size of ~25 μ L per drop. The neutralization assay buffer consists of 1x PBS, pH 7.4, containing 3% (w/v) BSA, 0.5% (v/v) Tween-20 and 0.05% (w/v) sodium azide.

A neutralization kinetic curve was generated for all seven antibodies at different concentrations to determine the percent neutralization against all four RBDs. Each antibody was diluted in neutralization assay buffer with antibody concentrations at 10, 2, 0.5, and 0.1 μ g/mL, and a zero-antibody control. The assays were run in stacking modes with each assay delaying for 30 seconds for up to 20 tests per run or delaying for 60 seconds for up to 10 tests per run. Each run took slightly more than 20 minutes, including 10 minutes of assay time and 10 minutes for reading all the test cassettes of the same run using an RDS-2500 LFA reader. For each cassette assay, an aliquot of 20 μ L diluted antibody solution was added to the sample port of a test cassette to start the assay. After the antibody sample absorbed for ~25 seconds, three drops (~75 μ L) of neutralization assay buffer was added to the sample port using a dropper bottle. The signal intensities of the test zone, the control zone, and a reference negative zone were measured at 10 minutes from the start of the assay using an RDS-2500 LFA reader. If the antibody has no neutralizing activity, the AuNP-RBD conjugate is captured by immobilized ACE2 at the test zone and a red test line is formed. If the antibody has neutralizing activity, then the antibody will bind to the AuNP-RBD and prevent it from being captured by immobilized ACE2, resulting in little to no signal. The cIgY control zone serves to verify (1) the biological reagents of the test strip are active, (2) the sample mixture and assay run buffer has flowed through the detection membrane properly, and (3) the performance of the neutralization assay buffer.

The reference negative zone, the entering area of the test view window of the test cassette serves as a general flow control.

Each test will have three intensity values – for the control zone, the test zone, and the reference negative zone. For the comparison of the neutralizing activity against SARS-CoV-2 and three variant RBDs, four sets of data were collected for each antibody. Two or three replicates were run for each antibody concentration, except the zero-antibody control with 6-8 replicates per test device type.

2.3. Calculation of the NC_{50} value for each neutralization kinetic curve

The NC_{50} in $\mu\text{g/mL}$ is the concentration of antibody that yields a 50% inhibition or neutralization of the maximal RBD-ACE2 binding capacity for a given neutralization cassette type.

To calculate the NC_{50} value per device type for each antibody, the mean signal intensity of the test zone at the zero-antibody concentration was calculated to represent the maximum RBD-ACE2 binding activity (i.e. 0% neutralization). When an antibody has neutralization activity, the binding capacity of the AuNP-RBD to immobilized ACE2 is reduced. The difference between the observed binding activity of each test and the maximum binding activity is the neutralization activity, which is then converted to individual %Neutralization. The %Neutralization of each individual test was calculated using the conversion formula shown below:

$$\left(\begin{array}{l} \% \text{Neutralization of individual test} = \\ \left[\text{Mean intensity}_{\text{zero-Ab}} - \text{Signal Intensity}_{\text{individual test}} \right] / \text{Mean Intensity}_{\text{zero-Ab}} \end{array} \right)$$

The mean %Neutralization was calculated from the converted %Neutralization replicate values for each test condition. A scatterplot was generated using the antibody concentration as the x-axis and the mean %Neutralization value as the y-axis. A semi-logarithmic curve fitting was performed for the determination of the NC_{50} value of each antibody against all RBDs (**Figure 2**).




Figure 2. Collection of signal intensities and flowchart for the calculation of NC_{50} values from the test line signal intensity. **(A)** An example of test cassette image recorded by the RDS-2500 LFA reader with designated zones for collection of signal intensities. **(B)** Flowchart for the calculation of the NC_{50} value for each neutralization kinetic curve.

2.4. Instrumentation and statistics

The NanoDrop 2000 spectrophotometer was purchased from Thermo Fisher Scientific (Waltham, MA). The RDS-2500 LFA reader was acquired from Detekt Biomedical LLC (Austin, TX) with the default R/G/B of 0/1/0 settings. Matrix 2360 Programmable Shear was purchased from Kinematic Automation (Sonora, CA). IsoFlow reagent dispenser was purchased from Imagene Technology (Lebanon, NH). All calculations were carried out using Microsoft Excel.

3. Results

3.1. Antibody pairing capability and epitope binning using SARS-CoV-2 RBD

Seven anti-SARS-CoV-2 RBD antibodies were studied for their pairing capability and epitope binning using a lateral flow dipstick immunoassay. These antibodies were spotted onto lateral flow nitrocellulose membranes as capture agents, and then reacted with SARS-CoV-2 RBD in the presence of one Ab-AuNP conjugate as detection agent. A non-competing antibody will pair and form a sandwich immunocomplex with the SARS-CoV-2 RBD, appearing as a dark red colored crescent line or spot on the nitrocellulose membrane. A competing antibody will not form a sandwich immunocomplex, appearing as a light red colored spot or no spot at all. The sandwich immunoassay principle is shown in **Figure 3A**. The immunodetection results for each detector anti-RBD Ab-AuNP conjugate and the negative control anti-NP Ab-AuNP conjugate are presented in **Figure 3B-3I**. Based on the binding pattern and pairing capability, these antibodies were grouped into three distinct epitope bins: bin A (Ab1 and Ab4), bin B (Ab2 and Ab5), and bin C (Ab3, Ab6 and Ab7) (**Table 1**). The fact that these seven monoclonal antibodies were generated through three distinct fusions along with the classification of these antibodies into three epitope bins, suggests that these epitopes constitute dominant antigenic domains of SARS-CoV-2 RBD and play a very important role in the natural immune response to SARS-CoV-2 infection and, presumably, vaccination.




Figure 3. Antibody pairing capability and epitope binning. (3A). Sandwich immunoassay principle. (3B-3I). Photographs of a representative set of lateral flow dipstick assays. Each dipstick has 9 spots: 7 spots for the antibodies of interest, and 2 spots for negative controls (anti-NP antibody and BSA). (**Note 1**). A dark red colored crescent line or circular spot indicates strong binding activity, a light red colored crescent line or circular spot indicates weak

binding activity, and an empty spot indicates no binding activity. (**Note 2**) All Ab-AuNP conjugates used were coated with 50 µg antibody per mL of 20 OD AuNP solution, except Ab7-AuNP was coated with 20 µg antibody per mL 20 OD AuNP. For anti-nucleocapsid antibodies, clone 1035138 (N) was used as a capture negative control and clone 1035101 (anti-NP) was used as a detector negative control.

Detector	Epitope Bin A	Epitope Bin B	Epitope Bin C
	Ab1 and Ab4	Ab2 and Ab5	Ab3, Ab6 and Ab7
Capture	Ab2, Ab3, Ab5, Ab6 & Ab7	Ab1, Ab3, Ab4, Ab6 & Ab7	Ab1, Ab2, Ab4 & Ab5

Table 1. Epitope bin and pairing summary.

3.2. Comparative binding characteristics to three variant RBDs vs. SARS-CoV-2 RBD

To investigate whether the above antibody pairings could detect the UK, SA, and BR P.1 variant RBDs, similar dipstick sandwich immunoassays were performed using the same capture antibody panel along with three representative epitope bin detectors, Ab4-AuNP, Ab5-AuNP, and Ab6-AuNP conjugates. Our initial experiment showed that the Ab7-Ab4 (capture/detector) pair discriminatively detects the four RBDs. Specifically, the SARS-CoV-2 and UK RBDs were strongly detected and the SA and BR P.1 RBDs were weakly detected by the Ab7-Ab4-AuNP pair. All other pairing options that were tested did not show discriminative detection of these four RBDs.

To confirm these discriminative binding characteristics, dipstick immunoassays were carried out using serially diluted RBD protein solutions, ranging from 0.001 µg/mL to 1 µg/mL. Since Ab6 and Ab7 belong to the sample epitope bin, only the Ab4-AuNP and Ab5-AuNP detectors were used in this confirmatory study. As shown in **Figure 4A**, with the Ab5-AuNP as the detector and the antibodies Ab1, Ab3, Ab4, Ab6 and Ab7, as capture agents, all pairing options strongly detected all four RBDs with a detection sensitivity of 0.001 µg/mL. Similarly, with the Ab4-AuNP as the detector (**Figure 4B**) and the antibodies Ab2, Ab3, Ab5 and Ab6 as capture agents, all pairing options detected all four RBDs with a detection sensitivity of 0.01 µg/mL. Overall, Ab5-AuNP appeared to have a better detection sensitivity than Ab4-AuNP as detector.

Interestingly, when the Ab4-AuNP detector was paired with Ab7 as the capture agent, the SARS-CoV-2 and UK RBDs were strongly detected with a detection sensitivity of 0.01 µg/mL; however, the SA and BR P.1 RBDs were weakly detected with a detection sensitivity between 0.1-1.0 µg/mL. This discriminative binding behavior of the Ab7-Ab4 pair for the detection of SARS-CoV-2 RBD and the three variant RBDs was also observed when Ab7 was paired with Ab1 (another bin A epitope antibody). Given that the Ab5-AuNP pairing with Ab7 capture strongly detected the SA and BR P.1 RBDs and that the Ab4-AuNP pairing with antibodies Ab2, Ab3, Ab5 and Ab6 also strongly detected the SA and BR P.1 RBDs, both AB7 and Ab4 appear to bind to the SA and BR P.1 RBDs well alone. Thus, the weak binding activity of the Ab7-Ab4 pair (and Ab7-Ab1 pair) to the SA and BR P.1 RBDs, as compared to the SARS-CoV-2 and UK RBDs, indicates that the E484K and K417N/T mutations contained in the SA and BR P.1 RBDs most likely induced conformational changes near or within the epitopes of where these antibodies bind. The conformational change could result in steric interference between Ab7 and bin A epitope antibodies.




Figure 4. Comparative binding characteristics to four RBDs using Ab4-AuNP and Ab5-AuNP as detectors. Representative photographs of test results. **(A)** Binding behavior of Ab5-AuNP conjugate to four RBDs. **(B)** Binding behavior of Ab4-AuNP conjugate to four RBDs. **(Note 1)** Solid arrow in dipsticks (A11, A12, B3, B4) indicates similar signal intensity at Ab7 spot. Open arrow in dipsticks (B7, B8, B11 and B12) indicates very faint or invisible signal at Ab7 spot. **(Note 2)** Both Ab4-AuNP and Ab5-AuNP conjugates were coated at 20 µg antibody per mL 20 OD AuNP solution.

3.3 Neutralizing kinetics of individual antibody and combination of antibodies

To investigate the neutralization kinetics of these antibodies with the three variant RBDs in comparison to the SARS-CoV-2 RBD, lateral flow neutralization cassette assays were carried out using rapid neutralizing antibody test devices for the SARS-CoV-2, the UK, the SA, and the BR P.1 RBDs. The lateral flow neutralization test principle is illustrated in **Figure 5A**. Essentially, AuNP-RBD conjugates are captured by immobilized ACE2 protein in the absence of a neutralizing antibody, forming a red-colored line at the test zone; but if a neutralizing antibody is present then it will bind to the AuNP-RBD

and prevent the AuNP-RBD from being captured by immobilized ACE2 protein. The signal intensity of the test zone is inversely correlated with the concentration of the neutralizing antibody. The signal intensity of the control zone is not affected by the neutralizing antibody. A representative set of lateral flow neutralizing antibody test cassettes is depicted in **Figure 5B**.




Figure 5. Neutralizing antibody test principle and images of representative test devices. **(A)** Lateral flow cassette neutralization assay principle. **(B)** Photographs of a representative set of lateral flow neutralization test devices. (Units = neutralizing antibody concentration in $\mu\text{g/mL}$).

The neutralization kinetics of each individual antibody against SARS-CoV-2 RBD and three variant RBDs was studied using serially diluted antibody solutions targeting antibody concentrations at 10, 2, 0.5, 0.1 and 0 $\mu\text{g/mL}$ suspended in neutralization assay buffer (**Figure 6A-6G**). The NC_{50} value was determined from the signal intensity of the test zone as described in the method section (**Figure 2B**). Five antibodies (Ab1, Ab2, Ab4, Ab6 and Ab7) showed strong neutralizing activity against SARS-CoV-2 RBD with NC_{50} values between 0.34 and 1.43 $\mu\text{g/mL}$ and two antibodies (Ab3 and Ab5) showed a moderate neutralizing activity against SARS-CoV-2 RBD with an NC_{50} value of 1.66 and 3.27 $\mu\text{g/mL}$, respectively, indicating that the epitopes of these seven antibodies are all near or in the RBD interface zone. The NC_{50} values for the seven antibodies against all four RBDs were summarized in **Table 2**.

With regard to the UK, SA and BR P.1 variant RBDs, two antibodies, Ab1 and Ab4 of bin A, maintained strong neutralizing activity against all three variant RBDs with NC_{50} values between 0.69 and 1.08 $\mu\text{g/mL}$, suggesting that these two antibodies target an epitope that is not affected by the mutations (N501Y, E484K and K417N/T) contained in these three variant RBDs. The remaining five monoclonal antibodies either partially or completely lost their neutralizing activity against at least one variant RBD. Antibody Ab7 showed strong neutralizing activity against the SARS-CoV-2 and UK RBDs with an NC_{50} value of 0.34 and 0.86 $\mu\text{g/mL}$, respectively, but completely lost its neutralizing

activity against the SA and BR P.1 RBDs with an NC_{50} value at greater than 45 $\mu\text{g/mL}$ (not able to precisely calculate it due the flat curve shape). This indicates that the Ab7 epitope is not affected by the shared N501Y mutation, but very likely is affected by the E484K and/or K417N/T mutations. Antibody Ab5 showed reduced neutralizing activity against SARS-CoV-2 RBD with an NC_{50} value of 3.27 $\mu\text{g/mL}$. This reduction in neutralizing activity was even greater for the three variant RBDs with NC_{50} values between 24 and 45 $\mu\text{g/mL}$. This suggests that the Ab5 epitope is in the proximity of the N501Y mutation, which is the only mutation shared among the UK, SA and BR P.1 RBDs.




Figure 6. Neutralization kinetics by lateral flow cassette neutralization assays. (6A-6G) Kinetic curves for individual antibodies against the four RBDs. (6H) Kinetic curve for the combined two antibodies against the four RBDs.

We then evaluated the neutralization activity of an antibody cocktail, combining Ab1 of bin A epitope and Ab2 of bin B epitope (**Figure 6H**). We observed a partial additive effect in the neutralizing activity of this antibody cocktail against the SARS-CoV-2 RBD and all three variant RBDs yielding NC_{50} values between 0.46 and 0.82 $\mu\text{g/mL}$, which are all less than their corresponding NC_{50} values of Ab1 (between 0.63 and 1.08 $\mu\text{g/mL}$) or Ab2 (between 1.35 and 1.83 $\mu\text{g/mL}$) alone. These results indicate that a combination of two or three antibodies of different epitope bins could be used to enhance the

neutralization capabilities of a therapeutic cocktail and that such an enhancement can be readily characterized by this lateral flow neutralization cassette assay.

Neutralization Target	NC ₅₀ (µg/mL)							
	Ab1	Ab2	Ab1+Ab2	Ab3	Ab4	Ab5	Ab6	Ab7
SARS-CoV-2 RBD	0.63	1.43	0.50	1.66	0.69	3.27	0.66	0.34
UK variant RBD	1.08	1.35	0.82	1.51	0.95	27.63	2.72	0.86
South African variant RBD	0.91	1.83	0.66	3.19	0.70	24.03	1.14	**
Brazilian P.1 variant RBD	0.70	1.40	0.46	2.21	0.69	44.79	1.11	**

Table 2. NC₅₀ summary table. Semi-logarithmic curve fitting was used to extrapolate the NC₅₀ values. For antibody Ab5, the range of 0.5–10 µg/mL was used for curve fitting. For other six antibodies and the combined antibodies, the range of 0.1–10 µg/mL was used for curve fitting. (**Note 1**) Strong neutralizing activity (light green): NC₅₀ < 1.5 µg/mL; Moderate neutralizing activity (light blue): 1.5 µg/mL ≤ NC₅₀ < 15 µg/mL; Weak or no neutralizing activity (orange): NC₅₀ ≥ 15 µg/mL. (**Note 2**) ** Indicate that the NC₅₀ value was not calculated due to flat nature of the curve and the very weak neutralizing activity.

3.4. Analysis and functional epitope arrangement map

Based on the binding characteristics and the neutralization activity against the SARS-CoV-2 RBD and all three variant RBDs, a functional arrangement map of these seven antibodies versus each RBD was generated. For the sandwich immunodetection of the SARS-CoV-2 RBD, these antibodies paired freely among the three epitope bins (**Figure 7A**). Five antibodies (Ab1, Ab2, Ab4, Ab6 and Ab7) showed strong neutralizing activity with an NC₅₀ value less than 1.5 µg/mL and two antibodies (Ab3 and Ab5) showed a moderate neutralizing activity with an NC₅₀ value between 1.5 and 15 µg/mL. Overall, these seven antibodies paired freely among the three epitope bins and showed moderate to strong neutralizing activities against the SARS-CoV-2 RBD.

Similar to the SARS-CoV-2 RBD, these antibodies paired freely among the three epitope bins for sandwich immunodetection of the UK RBD (**Figure 7B**). However, their neutralizing activity differs significantly. Four antibodies (Ab1, Ab2, Ab4 and Ab7) showed strong neutralizing activity against the UK RBD, with an NC₅₀ value less than 1.5 µg/mL, two antibodies (Ab3 and Ab6) had moderate neutralizing activity with an NC₅₀ values between 1.5 and 15 µg/mL, and one antibody (Ab5) had weak neutralizing activity with an NC₅₀ value of 27.63 µg/mL. The reduced neutralizing activity of Ab5 against the UK RBD is likely caused by the N501Y mutation – the only reported mutation contained in the UK variant RBD.

The SA and BR P.1 RBDs showed similar binding and neutralizing characteristics to these seven antibodies. For sandwich immunodetection of these two variant RBDs, these antibodies can pair freely among the three epitope bins, except the pairing of Ab7 (capture) and bin A epitope antibodies as detector. Unlike the SARS-CoV-2 and UK RBDs, when antibody Ab7 was used as a capture agent and then paired with Ab1 or Ab4 of bin A epitope, the detection of both SA RBD and BR P.1 RBD in the sandwich assay format was significantly reduced (**Figure 7C/D**). Five antibodies (Ab1, Ab2, Ab3, Ab4 and Ab6) had either strong or moderate neutralizing activity against these two RBDs with NC₅₀ values less than 15 µg/mL. Consistent with the reduced neutralizing activity for the UK RBD, antibody Ab5 had weak neutralizing activity against the SA and BR P.1 RBDs with NC₅₀ values greater than 15 µg/mL. Furthermore, antibody Ab7 did not show any neutralizing activity against the SA and BR P.1 RBDs at the concentration range tested. The E484K and/or K417N/T mutations contained in the SA and BR P.1 RBDs very likely influenced Ab7 to lose the neutralizing activity.




Figure 7. Functional arrangement map of the antibody pairing capability and neutralizing activity. (**Note 1**) Blue circle – Epitope bin A antibodies (Ab1 and Ab4); Green circle - Epitope bin B antibodies (Ab2 and Ab5); Orange circle – Epitope bin C antibodies (Ab3, Ab6, and Ab7). (**Note 2**) Red double-headed arrow indicates antibody pairing with strong detection capability; Yellow double-headed arrow indicates antibody pairing with weakened detection capability. (**Note 3**) Black dotted line indicates the neutralization functionality – if inside the dotted line, strong neutralization activity; if on or outside the dotted line, weak or no neutralization activity.

4. Discussion

SARS-CoV-2 spike protein is a critical component for SARS-CoV-2 to adhere to and enter mammalian cells [11,12]. The spike protein and its RBD are highly antigenic and have been the primary target of numerous recently developed vaccines and therapeutics [13-16]. Given that the seven antibodies evaluated in this report were generated from three distinct fusions, the classification of these antibodies into three epitope bins by virtue of their binding and neutralization characteristics suggests that their corresponding target regions on the RBD protein belong to dominant antigenic epitopes, which could elicit protective humoral immune responses to the SARS-CoV-2 infection or vaccination. The two antibodies of bin A epitope, Ab1 (clone 1035709) and Ab4 (clone 1035762), exhibited broad and potent neutralization activity against all four RBDs and offer a useful insight in the development of therapeutic antibody for emerging virus variants. While more studies are required to more definitively identify the epitopes we have revealed, our studies suggest that therapeutic antibodies targeting epitopes similar to bin A are likely to provide better protection against the UK, SA, and BR P.1 variants, while therapeutic antibodies targeting epitopes similar to bin B and bin C are more likely escaped by these variants. Based on studies showing that three variants (UK, SA and BR P.1 RBD mutants) escaped the therapeutic LY-CoV555 antibody and two variants (SA and BR P.1 RBD mutants) escaped the LY-CoV016 antibody, Starr et al. suggested that both the SA and the BR P.1 variants may also escape the antibody cocktail of LY-CoV555 and LY-CoV016 [21]. Thus, having rapid tools available to study neutralization activities of antibodies along with further elucidation of the exact nature of the epitopes recognized by our bin A antibodies (Ab1 and Ab4) could provide a useful framework for the rapid development of therapeutic cocktails against the constantly emerging SARS-CoV-2 variants.

Although numerous factors can affect the binding of SARS-CoV-2 spike protein to the ACE2 receptor [23], the virus spike protein RBD plays a central role for this interaction [11,12]. The N501Y RBD mutation, first found in the UK variant [3], has been demonstrated to exhibit stronger interaction force with ACE2 receptor, which is associated with increased infectivity of the UK variant [2, 8, 24]. With regard to the impact of N501Y mutation on the escape of neutralizing antibody, Supasa et al. [25] reported that the UK variant is not neutralized as easily as SARS-CoV-2 by convalescent sera, vaccine sera and some anti-RBD monoclonal antibodies, while Xie et al. [18] observed only a small reduction in neutralization activity against the UK variant by sera elicited by two doses of the Pfizer vaccine BNT162b2. Our results demonstrated that Ab5 had significantly reduced neutralizing activity (NC_{50} : > 15 μ g/mL) against the UK, SA and BR P.1 variant RBDs, suggesting that the shared N501Y mutation not only increases ACE2-RBD interaction [2],

but also contributes to the escape phenomenon of neutralizing antibody. Together, this may explain the weakened efficacy of vaccines or therapeutic antibodies against these variants.

As to the E484K mutation characteristic of the SA and BR P.1 variant RBDs, was reported to be "associated with escape from neutralizing antibodies" which adversely affects the efficacy of spike protein dependent COVID-19 vaccines [26]. Several studies have demonstrated that spike-targeted vaccines or convalescent plasma from SARS-CoV-2 infected human subjects are less effective in neutralizing the South African variant [27]. In fact, Moderna Inc recently initiated a clinical trial using a modified version of spike RNA vaccine to counter the South African and perhaps other known variants [28]. Our results that both the SA and BR P.1 variants RBDs completely escaped Ab7 neutralization confirmed that the E484/K417 mutations may be directly involved with the escape mechanism. Further characterization of antibody Ab7 epitope could shed light on better understanding how to focus the humoral immune response to these challenging epitopes and avoid the escape mechanism of SARS-CoV-2. Additionally, having rapid test tool for clinical diagnostics and epidemiological studies for SARS-CoV-2 variant infection could prove useful in situations where timing to the development of effective clinical tools is mission critical.

Being able to monitor multiple parameters of potential antibody candidates is key to being able to make the right decisions on antibody selections for clinical utility. For example, Ab7 of bin C pairing with antibody Ab4 (and Ab1) of bin A showed very weak binding activity to the SA and BR P.1 RBDs in sandwich immunoassay format; however Ab7 pairing with Ab5 and Ab2 of bin B did not show any apparent difference in the binding activities to all four RBDs studied. This discriminative binding behavior to the four RBDs suggests that the E484K and/or K417N/T mutations have likely induced conformational changes near the epitopes where these antibodies bind to in the SA and BR P.1 variant RBDs. This in turn may have resulted in steric interference between Ab7 and bin A antibodies, but no apparent steric interference between Ab7 and bin B antibodies. Furthermore, such a mutation-induced conformational change of the spike molecule could contribute to the escape phenomenon of antibody Ab7 by the SA and BR P.1 variant RBDs. Since the neutralization activities of bin A antibodies (Ab1 and Ab4) are not affected by the three mutations contained in the UK, SA and BR P.1 variant RBDs, further investigation on the mechanism by which the E484K and/or K417N/T alters the binding and neutralizing activities of these antibodies may help in the identification of a better therapeutic epitope target.

Lateral flow assays are commonly used for rapid clinical testing, such as COVID-19 serological tests, antigen tests, certain molecular tests, and the neutralizing antibody test [29-33]. Wang et al. have reported the use of a lateral flow dipstick assay with wild-type and the South African spike S1 protein for the characterization of the neutralizing activity of post-vaccination plasma samples [29]. Our observation that the calculated NC_{50} values of five mouse monoclonal antibodies to the SARS-CoV-2 RBD are between 0.3 and 1.5 $\mu\text{g/mL}$ appears to be consistent with a reported IC_{50} of 1.402 $\mu\text{g/mL}$ for a mouse monoclonal antibody using a dipstick assays [29]. Our studies demonstrated that sandwich-based immunoassays, such as lateral flow assays, offer an attractive and cost-effective alternative in characterizing antibody binding properties, epitope binning, and in vitro neutralizing kinetics of therapeutic antibodies and cocktails. In addition, our lateral flow based rapid neutralizing antibody tests could potentially be used to assess the neutralizing antibody activities against SARS-CoV-2 RBD and the UK, SA and BR P.1 variant RBDs of human blood samples.

5. Patent

The work presented in this report was part of a provisional patent application filed at the USA patent office. No decision has been taken to this point.

Data Availability Statement: The data reported in this report are available from the authors upon request.

Author Contributions: Conceptualization, K.G., F.M., S.B., and E.T.; methodology, E.T., E.F., J.C., and M.B.; software, n/a; validation, E.T., E.F., M.H., and A.M.; formal analysis, E.T.; investigation, E.T., E.F., M.H., A.M., S.A., J.C., and J.Hu.; resources, J. Hu., J.L., and M.B.; data curation, E.T., E.F., and S.B.; writing—original draft preparation, E.T. and F.M.; writing—review and editing, J. Ha., M.H., E.F., J. Hu., J.C., A.P., and A.M.; visualization, E.T., F.M., and M.H.; supervision, S.B. and K.G.; project administration, n/a; funding acquisition, n/a. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).

Conflicts of Interest: All authors from Bio-Techne Corporation could be holders of Bio-Techne stock or stock options.

References

1. Abdool Karim, S.S.; de Oliveira, T. New SARS-CoV-2 variants - clinical, public health, and vaccine implications. *N. Engl. J. Med.* **2021** *384*, 1866–1868. doi: 10.1056/NEJMc2100362.
2. Santos, J.C.; Passos, G.A. The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation. *bioRxiv preprint*, **2021**. doi: 10.1101/2020.12.29.424708. (accessed on 21 May 2021).
3. Rambaut, A.; Loman, N.; Pybus, O.G.; Barclay, W.; Barrett, J.; Carabelli, A.; Connor, T.; Peacock, T.; Robertson, D.L.; Volz, E.; et al. Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. *Virological.org*, **2020**. <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergentsars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>. (accessed on 21 May 2021).
4. Villoutreix B.O.; Calvez V.; Marcelin, A.-G.; and Khatib, A.-M. In silico investigation of the new UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 variants with a focus at the ACE2-spike RBD interface. *Int. J. Mol. Sci.* **2021**, *22*, 1695. doi: 10.3390/ijms22041695.
5. Faria, N.R.; Mellan, T.A.; Whittaker, C.; Claro, I.M.; Candido, D.S.; Mishra, S.; Crispim, M.A.M.; Sales, F.C.S.; Hawryluk, I.; McCrone, J.T.; et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science* **2021**. doi: 10.1126/science.abh2644.
6. Voloch, C.M.; Silva F., R.d.; de Almeida, L.G.P.; Cardoso, C.C.; Brustolini, O.J.; Gerber, A.L.; Guimarães, A.P.d.C.; Mariani, D.; Costa, R.M.d.; Ferreira, O.C.; et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. (BR P.2). *J. Virol* **2021**, *95*, e00119–21. doi: 10.1128/JVI.00119–21.
7. Bayarri-Olmos, R.; Rosbjerg A.; Johnsen, L.B.; Helgstrand, C.; Bak-Thomsen, T.; Garred, P.; Skjoedt, M.-O. The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization. *J. Biol. Chem.* **2021**, *296*, 100536. doi: 10.1016/j.jbc.2021.100536.
8. Zhang, W.; Davis, B.D.; Chen, S.S.; Sincuir Martinez, J.M.; Plummer, J.T.; Vail, E. Emergence of a novel SARS-CoV-2 variant in Southern California. *JAMA* **2021**, *325*, 1324–1326. doi: 10.1001/jama.2021.1612.
9. Annavajhala, M.K.; Mohri, H.; Zucker, J.E.; Sheng, Z.; Wang, P.; Gomez-Simmonds, A.; Ho, D.D.; Uhlemann, A.-C. A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York. *medRxiv preprint* **2021**, doi: 10.1101/2021.02.23.21252259. (accessed on 21 May 2021).
10. Cherian, S.; Potdar, V.; Jadhav, S.; Yadav, P.; Gupta, N.; Das, M.; Das, S.; Agarwal, A.; Singh, S.; Abraham, P.; et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. *bioRxiv preprint* **2021**. doi: 10.1101/2021.04.22.440932. (accessed on 21 May 2021).
11. Ou, X.; Liu, Y.; Lei, X.; Li, P.; Mi, D.; Ren, L.; Guo, R.; Chen, T.; Hu, J.; et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun.* **2020**, *11*, 1620. doi: 10.1038/s41467-020-15562-9.
12. Shang, J.; Wan, Y.; Luo, C.; Ye, G.; Geng, Q.; Auerbach, A.; Li, F. Cell entry mechanisms of SARS-CoV-2. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 11727–11734. doi: 10.1073/pnas.2003138117.
13. Jackson, L.A.; Anderson, E.J.; Roupheal, N.G.; Roberts, P.C.; Makhene, M.; Coler, R.N.; McCullough, M.P.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. *N. Engl. J. Med.* **2020**, *383*, 1920–1931. doi: 10.1056/NEJMoa2022483.

14. Mulligan, M.J.; Lyke, K.E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Raabe, V.; Bailey, R.; Swanson, K.A.; et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* **2020**, *586*, 589-593. doi: 10.1038/s41586-020-03098-3.
15. Food and Drug Administration. Letter to Regeneron Pharmaceuticals, Inc. (21 Nov 2020). <https://www.fda.gov/media/143891/download>. (accessed on 18 May 2021).
16. Food and Drug Administration. Letter to Eli Lilly and Company. (25 February 2021). <https://www.fda.gov/media/145801/download>. (accessed on 19 May 2021).
17. Zoufaly, A.; Poglitsch, M.; Aberle, J.H.; Hoepler, W.; Seitz, T.; Traugott, M.; Grieb, A.; Pawelka, E.; Laferl, H.; Wenisch, C.; et al. Human recombinant soluble ACE2 in severe COVID-19. *Lancet Respir. Med.* **2020**, *8*, 1154-1158. doi: 10.1016/S2213-2600(20)30418-5.
18. Xie, X.; Liu, Y.; Liu, J.; Zhang, X.; Zou, J.; Fontes-Garfias, C.R.; Xia, H.; Swanson, K.A.; Cutler, M.; Cooper, D.; et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat. Med.* **2021**, *27*, 620-621. doi: 10.1038/s41591-021-01270-4.
19. Hansen, J.; Baum, A.; Pascal, K.E.; Russo, V.; Giordano, S.; Wloga, E.; Fulton, B.O.; Yan, Y.; Koon, K.; Patel, K.; et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science* **2020**, *369*, 1010-1014. doi: 10.1126/science.abd0827.
20. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. (April 16, 2021) <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab>. (accessed on 18 May 2021).
21. Starr, T.N.; Greaney, A.L.; Dingens, A.S.; Bloom, J.D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. *Cell Rep. Med.* **2021**, *2*, 100255 (p1-p6). doi: 10.1016/j.xcrm.2021.100255.
22. NCBI Reference Sequence: YP_009724390.1. Surface glycoprotein [Severe acute respiratory syndrome coronavirus 2]. <https://www.ncbi.nlm.nih.gov/protein/1796318598>. (accessed on 18 May 2021).
23. Chi, X.; Yan, R.; Zhang, J.; Zhang, G.; Zhang, Y.; Hao, M.; Zhang, Z.; Fan, P.; Dong, Y.; Yang, Y.; et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science* **2020**, *369*, 650-655. doi: 10.1126/science.abc6952.
24. Gu, H.; Chen, Q.; Yang, G.; He, L.; Fan, H.; Deng, Y.-Q.; Wang, Y.; Teng, Y.; Zhao, Z.; Cui, Y.; et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. *Science* **2020**, *369*, 1603-1607. doi: 10.1126/science.abc4730.
25. Supasa, P.; Zhou, D.; Dejnirattisai, W.; Liu, C.; Mentzer, A.J.; Ginn, H.M.; Zhao, Y.; Duyvesteyn, H.M.E.; Nutalai, R.; Tuekprakhon, A.; et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. *Cell* **2021**, *184*, 2201-2211. doi: 10.1016/j.cell.2021.02.033.
26. Weisblum, Y.; Schmidt, F.; Zhang, F.; DaSilva, J.; Poston, D.; Lorenzi, J.C.C.; Muecksch, F.; Rutkowska, M.; Hoffmann, H.-H.; Michailidis, E.; et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *eLife* **2020**, *9*, e61312. doi: 10.7554/eLife.61312.
27. Hoffmann, M.; Arora, P.; Groß, R.; Seidel, A.; Hörnich, B.F.; Hahn, A.S.; Krüger, N.; Graichen, L.; Hofmann-Winkler, H.; Kempf, A.; et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. *Cell* **2021**, *184*, 2384-2393. doi: 10.1016/j.cell.2021.03.036.
28. NIH clinical trial evaluating Moderna COVID-19 variant vaccine begins. (March 31, 2021) <https://www.nih.gov/news-events/news-releases/nih-clinical-trial-evaluating-moderna-covid-19-variant-vaccine-begins>. (accessed on 18 May 2021).
29. Wang, J.J.; Zhang, N.; Richardson, S.A.; Wu, J.V. Rapid lateral flow tests for the detection of SARS-CoV-neutralizing antibodies. *Expert Rev. Mol. Diagn.* **2021**, 1-8. doi: 10.1080/14737159.2021.1913123.
30. Lake, D.F.; Roeder, A.J.; Kaleta, E.; Jasbi, P.; Periasamy, S.; Kuzmina, N.; Bukreyev, A.; Grys, T.; Wu, L.; Mills, J.R.; et al. Development of a rapid point-of-care test that measures neutralizing antibodies to 2 SARS-CoV-2. *medRxiv preprint* **2021**. doi: 10.1101/2020.12.15.20248264. (accessed on 21 May 2021).
31. Tan, C.W.; Chia, W.N.; Qin, X.; Liu, P.; Chen, M.I.-C.; Tiu, C.; Hu, Z.; Chen, V.C.-W.; Young, B.E.; Sia, W.R.; et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nature Biotech* **2020**, *38*, 1073-1078. doi: 10.1038/s41587-020-0631-z.
32. United States FDA - In Vitro Diagnostics EUAs. (content as current as 04/20/2021) <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>. (accessed on 18 May 2021).
33. Oyewole, A.O.; Barrass, L.; Robertson, E.G.; Woltmann, J.; O'Keefe, H.; Sarpal, H.; Dangova, K.; Richmond, C.; Craig, D. COVID-19 Impact on Diagnostic Innovations: Emerging Trends and Implications. *Diagnostics* **2021**, *11*, 182. doi: 10.3390/diagnostics11020182.